Concluding remarks
MOGAD pathophysiology, disease treatment, and monitoring are currently
of high interest in the autoimmune neuroinflammatory diseases research
community. So far, most known MRI and OCT characteristics in MOGAD are
based on small monocentric studies that yielded some contradicting
results, thus multi-centred and prospective studies are necessary to
validate findings. Such multi-centred studies are beginning to shed
light on this rare disease, such as the Collaborative OCT in NMOSD
(CROCTINO) and the PArallel MRI in NMOSD (PAMRINO) studies (133).
In vivo imaging, using MRI and OCT, has given clinicians and researchers
insights into the central nervous system affection of this rare disorder
at an unprecedented rate. As new technologies and analysis methods
continue to be developed, along with the increase in open-sharing and
collaborative, prospective studies on the horizon; we believe both MRI
and OCT will lead the way towards personalised prognostics and treatment
in MOGAD.